Michael H. Davidson to Coronary Disease
This is a "connection" page, showing publications Michael H. Davidson has written about Coronary Disease.
Connection Strength
6.379
-
Intensive statin therapy in India: Demonstrating efficacy and safety. Indian Heart J. 2016 Nov - Dec; 68(6):756-757.
Score: 0.520
-
Focusing on high-density lipoprotein for coronary heart disease risk reduction. Cardiol Clin. 2011 Feb; 29(1):105-22.
Score: 0.352
-
Lp-PLA2: A new target for statin therapy. Curr Atheroscler Rep. 2010 Jan; 12(1):29-33.
Score: 0.327
-
An urgent matter-identifying your patients' cardiovascular risk and improving their outcomes. Assessing cardiovascular risk one patient at a time. J Fam Pract. 2009 Nov; 58(11 Suppl Urgent):S26-31.
Score: 0.323
-
Is LDL-C passed its prime? The emerging role of non-HDL, LDL-P, and ApoB in CHD risk assessment. Arterioscler Thromb Vasc Biol. 2008 Sep; 28(9):1582-3.
Score: 0.298
-
Safety of aggressive lipid management. J Am Coll Cardiol. 2007 May 01; 49(17):1753-62.
Score: 0.271
-
Socioeconomic status in relationship to death of vascular disease and late-life dementia. J Neurol Sci. 2007 Jun 15; 257(1-2):177-81.
Score: 0.270
-
Differences between clinical trial efficacy and real-world effectiveness. Am J Manag Care. 2006 Nov; 12(15 Suppl):S405-11.
Score: 0.262
-
Non-high-density lipoprotein cholesterol: the forgotten therapeutic target. Am J Cardiol. 2005 Nov 07; 96(9A):59K-64K; discussion 34K-35K.
Score: 0.244
-
Reducing residual risk for patients on statin therapy: the potential role of combination therapy. Am J Cardiol. 2005 Nov 07; 96(9A):3K-13K; discussion 34K-35K.
Score: 0.242
-
Torcetrapib/atorvastatin combination therapy. Expert Rev Cardiovasc Ther. 2005 Sep; 3(5):789-820.
Score: 0.242
-
Reducing cardiovascular risk: trends in risk, risk assessment, and cholesterol management. Postgrad Med. 2004 Sep; 116(3 Suppl):7-12.
Score: 0.226
-
Niacin: a powerful adjunct to other lipid-lowering drugs in reducing plaque progression and acute coronary events. Curr Atheroscler Rep. 2003 Sep; 5(5):418-22.
Score: 0.211
-
Cholesterol-lowering drugs bring benefits to high-risk populations even when LDL is normal. J Cardiovasc Nurs. 2003 Jan-Mar; 18(1):44-9; quiz 75-6.
Score: 0.201
-
Lipid management and the elderly. Prev Cardiol. 2003; 6(3):128-33; quiz 134-5.
Score: 0.201
-
A symposium: National Cholesterol Education Program Adult Treatment Panel III: Impact and implementation of the new guidelines. Introduction. Am J Cardiol. 2002 Mar 07; 89(5A):1C-2C.
Score: 0.190
-
Strategies to improve Adult Treatment Panel III guideline adherence and patient compliance. Am J Cardiol. 2002 Mar 07; 89(5A):8C-20C; discussion 20C-22C.
Score: 0.190
-
Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials). Am J Cardiol. 2018 04 15; 121(8):940-948.
Score: 0.143
-
Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial. J Clin Lipidol. 2015 Jan-Feb; 9(1):65-71.
Score: 0.114
-
Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease. Am J Cardiol. 2014 Jan 01; 113(1):76-83.
Score: 0.106
-
Indicators of the atherogenic lipoprotein phenotype measured with density gradient ultracentrifugation predict changes in carotid intima-media thickness in men and women. Vasc Health Risk Manag. 2012; 8:31-8.
Score: 0.094
-
Predictors of anterior and posterior wall carotid intima media thickness progression in men and women at moderate risk of coronary heart disease. J Clin Lipidol. 2011 May-Jun; 5(3):141-151.
Score: 0.088
-
Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010 Dec 16; 363(25):2406-15.
Score: 0.087
-
Effects of consumption of pomegranate juice on carotid intima-media thickness in men and women at moderate risk for coronary heart disease. Am J Cardiol. 2009 Oct 01; 104(7):936-42.
Score: 0.080
-
Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib. Am Heart J. 2009 Oct; 158(4):513-519.e3.
Score: 0.080
-
Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD. Am J Kidney Dis. 2009 May; 53(5):741-50.
Score: 0.077
-
Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. Atherosclerosis. 2008 Mar; 197(1):12-24.
Score: 0.071
-
Reduced treatment success in lipid management among women with coronary heart disease or risk equivalents: results of a national survey. Am Heart J. 2006 Nov; 152(5):976-81.
Score: 0.066
-
Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions. Expert Opin Drug Saf. 2006 Jan; 5(1):145-56.
Score: 0.062
-
Aggressive versus moderate lipid-lowering therapy in hypercholesterolemic postmenopausal women: Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES). Circulation. 2005 Jul 26; 112(4):563-71.
Score: 0.060
-
Clinical significance of statin pleiotropic effects: hypotheses versus evidence. Circulation. 2005 May 10; 111(18):2280-1.
Score: 0.059
-
Treating dyslipidemia in high-risk patients: case reviews and discussion. Postgrad Med. 2004 Sep; 116(3 Suppl):21-8.
Score: 0.056
-
Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin. Am J Cardiol. 2003 Mar 06; 91(5A):20C-23C; discussion 23C-24C.
Score: 0.051
-
Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002 Jul 03; 288(1):49-57.
Score: 0.049
-
A look to the future: new treatment guidelines and a perspective on statins. Am J Med. 2002 Jun 03; 112 Suppl 8A:34S-41S.
Score: 0.048
-
Subgroup interactions in the Heart and Estrogen/Progestin Replacement Study: lessons learned. Circulation. 2002 Feb 26; 105(8):917-22.
Score: 0.047
-
Management of hypercholesterolaemia in postmenopausal women. Drugs Aging. 2002; 19(3):169-78.
Score: 0.047
-
Statin trials in progress: unanswered questions. Curr Atheroscler Rep. 2001 Jan; 3(1):9-13.
Score: 0.044
-
Safety profiles for the HMG-CoA reductase inhibitors: treatment and trust. Drugs. 2001; 61(2):197-206.
Score: 0.044
-
Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE)-rationale and design of atorvastatin versus usual care in hypercholesterolemic patients with coronary artery disease. Am J Cardiol. 2000 Jul 15; 86(2):250-2.
Score: 0.042
-
Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease. Am J Cardiol. 1996 Aug 15; 78(4):409-14.
Score: 0.032
-
Myocardial viability in asynergic regions subtended by occluded coronary arteries: relation to the status of collateral flow in patients with chronic coronary artery disease. J Am Coll Cardiol. 1994 Mar 15; 23(4):860-8.
Score: 0.027
-
Value of metabolic imaging with positron emission tomography for evaluating prognosis in patients with coronary artery disease and left ventricular dysfunction. Am J Cardiol. 1994 Mar 15; 73(8):527-33.
Score: 0.027
-
Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies. J Clin Lipidol. 2012 Nov-Dec; 6(6):534-44.
Score: 0.024
-
Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by National Cholesterol Education Program risk category. Metab Syndr Relat Disord. 2009 Dec; 7(6):601-10.
Score: 0.020
-
Omega-3 fatty acid concentrates in the treatment of moderate hypertriglyceridemia. Expert Opin Pharmacother. 2008 May; 9(7):1237-48.
Score: 0.018
-
Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med. 2003 Mar 10; 163(5):553-64.
Score: 0.013
-
Effects of simvastatin, an HMG-CoA reductase inhibitor, in patients with hypertriglyceridemia. Clin Cardiol. 2003 Jan; 26(1):18-24.
Score: 0.013
-
Association between elevated plasma fibrinogen and the small, dense low-density lipoprotein phenotype among postmenopausal women. Am J Cardiol. 2000 Feb 15; 85(4):451-6.
Score: 0.010
-
Low-density lipoprotein subclass distribution pattern and adiposity-associated dyslipidemia in postmenopausal women. J Am Coll Nutr. 2000 Feb; 19(1):23-30.
Score: 0.010